The rise of Sildenafil initially fueled a period of growth for pharma, nevertheless recent changes present a complicated outlook for those considering a stake. Lower-cost alternatives are eating into earnings, and https://zoewjpv473043.targetblogs.com/41490798/the-blue-pill-and-big-pharma-a-risky-bet